Definitive Healthcare Corp. (DH) Stock Analysis and Metrics

Definitive Healthcare

NASDAQ: DH

$0.68 ▼ -0.01 (-1.21%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap72.23 Mn

P/E-0.31

P/S0.30

Div. Yield0.00

ROIC (Qtr)-0.07

Total Debt (Qtr)162.74 Mn

Revenue Growth (1y) (Qtr)-5.51

Add ratio to table…

About

Definitive Healthcare is a leading provider of healthcare data and analytics. The company delivers a software as a service platform that supplies comprehensive information on healthcare providers and their activities. It also offers claims and consumer analytics built from modeled data on millions of unique consumers. These capabilities help customers make informed decisions across product development go to market planning and sales and marketing execution. Definitive Healthcare serves three primary end markets: Life Sciences, Provider, and Diversified. As of December 31 2025 the company had approximately 2,330 customers.

Definitive Healthcare generates substantially all of its revenue from subscription fees for its software as a service products. Customers access the data offerings on a subscription basis and pay recurring fees for continued access to the platform. The revenue model relies on maintaining and expanding the base of paid subscribers.

The company operates through the following segments: Life Sciences, Provider, and Diversified.

• Life Sciences: Serves biopharmaceutical and medical device companies that need data for product development commercial strategy and market analysis.

• Provider: Serves hospitals health systems and other care delivery organizations seeking insights for sales marketing clinical operations and network management.

• Diversified: Serves healthcare information technology firms staffing agencies commercial real estate companies financial institutions and marketing and advertising agencies operating within the healthcare ecosystem.

Definitive Healthcare operates in a highly fragmented market for healthcare data and analytics. Its competitive advantage stems from a comprehensive dataset built over more than a decade proprietary data science capabilities and a user interface that delivers answers rather than raw data. Key competitors include legacy raw claims data providers such as Clarivate IQVIA and Symphony Health emerging point solution players like AcuityMD and MedScout niche healthcare specialists such as Komodo Health H1 Healthcare Trella Health and Trilliant Health ecosystem players such as SG2 and Veeva and horizontal go to market intelligence platforms such as ZoomInfo LinkedIn and Dun & Bradstreet. The company believes the principal competitive factors are depth breadth and accuracy of healthcare specific commercial intelligence healthcare subject matter expertise AI and data science capabilities ease of use and deployment and data privacy and security.

Definitive Healthcare serves a diverse customer base that includes biopharmaceutical and medical device companies hospitals health systems healthcare information technology firms staffing agencies commercial real estate companies financial institutions and marketing and advertising agencies. As of December 31 2025 the company reported approximately 2,330 customers with one or more active paid subscriptions.

Investment Thesis

▲ Bull case

Definitive Healthcare Corp. is positioned to capitalize on a structural shift in the healthcare data market where data quality and integration depth are becoming non-negotiable for life sciences and provider customers, a trend underscored by multiple six-figure win-backs in diversified and medtech segments during Q1 FY26. These wins were driven not by price competition but by customers recognizing that alternative vendors' incomplete datasets created unacceptable trust deficits and operational inefficiencies, particularly in identifying key opinion leaders and mapping prescription patterns—areas where Definitive Healthcare's proprietary claims, affiliation, and reference data provide unique longitudinal context. The company's recent fall expansion pack release, which restored claims data to or above historical levels, directly addresses the core pain point that had driven prior customer churn, and management's observation that renewal decisions made during the disruption period are now cycling out suggests a meaningful reduction in downside pressure on retention metrics. This is further supported by the year-over-year improvement in net dollar retention rate on a trailing 12-month basis, indicating that the foundational work on data differentiation is beginning to translate into stickier customer relationships and reduced churn risk, even as life sciences recovery lags.
The company's strategic pivot toward innovation and digital engagement, particularly the imminent launch of AI-enabled solutions later in Q2 FY26, represents a tangible catalyst that management did not emphasize as a near-term revenue driver but which could significantly enhance monetization pathways beyond traditional subscription models. By embedding a natural language interface into its existing platform, Definitive Healthcare Corp. aims to democratize data access across broader user bases within customer organizations, increasing utilization and expanding the addressable use cases for its data—such as enabling non-technical teams in sales, marketing, and clinical development to uncover insights previously restricted to analytics specialists. Early market feedback, including a third-party benchmark showing 63% higher click-through rates for its audiences versus a leading competitor, validates the commercial viability of its digital activation strategy, which is already generating bookings through over 30 agency partnerships (with more than half actively transacting). This shift transforms the company from a pure data vendor into a workflow-integrated intelligence provider, creating opportunities for incremental pricing, upsell to existing clients, and improved retention through heightened product stickiness—factors that are not fully reflected in current guidance but could accelerate the return to top-line growth sooner than anticipated.
Definitive Healthcare Corp.'s financial resilience, characterized by strong unlevered free cash flow generation (~$50 million TTM) and expanding adjusted EBITDA margins (27% in Q1 FY26, up 260 bps YoY), provides a durable foundation to weather near-term top-line pressures while funding strategic investments in AI, integrations, and data sourcing without compromising profitability. The margin expansion was driven by deliberate operational efficiencies, including a timing benefit from data source transitions and a shift toward capitalized software development (nearly $3 million in Q1 FY26, up >$1.5 million YoY), which reflects a disciplined reallocation of R&D spend toward innovation rather than mere cost-cutting. This financial flexibility allows the company to continue investing in high-impact areas like the new HubSpot and enhanced Salesforce integrations—which reduced average integration time from over 100 days to 45 days YoY—thereby increasing customer stickiness and renewal potential. Crucially, these investments are being made within a controlled expense framework, as evidenced by the company's ability to exceed EBITDA guidance despite a 6% YoY revenue decline, suggesting that the underlying business model remains fundamentally sound and capable of supporting growth reacceleration once the life sciences segment stabilizes and digital activation scales.

Definitive Healthcare Corp. is positioned to capitalize on a structural shift in the healthcare data market where data quality and integration depth are becoming non-negotiable for life sciences and provider customers, a trend underscored by multiple six-figure win-backs in diversified and medtech segments during Q1 FY26. These wins were driven not by price competition but by customers recognizing that alternative vendors' incomplete datasets created unacceptable trust deficits and operational inefficiencies, particularly in identifying key opinion leaders and mapping prescription patterns—areas where Definitive Healthcare's proprietary claims, affiliation, and reference data provide unique longitudinal context. The company's recent fall expansion pack release, which restored claims data to or above historical levels, directly addresses the core pain point that had driven prior customer churn, and management's observation that renewal decisions made during the disruption period are now cycling out suggests a meaningful reduction in downside pressure on retention metrics. This is further supported by the year-over-year improvement in net dollar retention rate on a trailing 12-month basis, indicating that the foundational work on data differentiation is beginning to translate into stickier customer relationships and reduced churn risk, even as life sciences recovery lags.
The company's strategic pivot toward innovation and digital engagement, particularly the imminent launch of AI-enabled solutions later in Q2 FY26, represents a tangible catalyst that management did not emphasize as a near-term revenue driver but which could significantly enhance monetization pathways beyond traditional subscription models. By embedding a natural language interface into its existing platform, Definitive Healthcare Corp. aims to democratize data access across broader user bases within customer organizations, increasing utilization and expanding the addressable use cases for its data—such as enabling non-technical teams in sales, marketing, and clinical development to uncover insights previously restricted to analytics specialists. Early market feedback, including a third-party benchmark showing 63% higher click-through rates for its audiences versus a leading competitor, validates the commercial viability of its digital activation strategy, which is already generating bookings through over 30 agency partnerships (with more than half actively transacting). This shift transforms the company from a pure data vendor into a workflow-integrated intelligence provider, creating opportunities for incremental pricing, upsell to existing clients, and improved retention through heightened product stickiness—factors that are not fully reflected in current guidance but could accelerate the return to top-line growth sooner than anticipated.
Definitive Healthcare Corp.'s financial resilience, characterized by strong unlevered free cash flow generation (~$50 million TTM) and expanding adjusted EBITDA margins (27% in Q1 FY26, up 260 bps YoY), provides a durable foundation to weather near-term top-line pressures while funding strategic investments in AI, integrations, and data sourcing without compromising profitability. The margin expansion was driven by deliberate operational efficiencies, including a timing benefit from data source transitions and a shift toward capitalized software development (nearly $3 million in Q1 FY26, up >$1.5 million YoY), which reflects a disciplined reallocation of R&D spend toward innovation rather than mere cost-cutting. This financial flexibility allows the company to continue investing in high-impact areas like the new HubSpot and enhanced Salesforce integrations—which reduced average integration time from over 100 days to 45 days YoY—thereby increasing customer stickiness and renewal potential. Crucially, these investments are being made within a controlled expense framework, as evidenced by the company's ability to exceed EBITDA guidance despite a 6% YoY revenue decline, suggesting that the underlying business model remains fundamentally sound and capable of supporting growth reacceleration once the life sciences segment stabilizes and digital activation scales.

▼ Bear case

Definitive Healthcare Corp. continues to face persistent structural headwinds in its life sciences segment, which remains the primary driver of the company's overall revenue decline despite modest gains in diversified and provider markets, and management's optimism about a near-term turnaround may be overstated given the segment's delayed response to strategic initiatives and ongoing macroeconomic pressures. While the company highlights repaired claims data levels and early win-backs as signs of recovery, life sciences revenue remains depressed due to a fundamental shift in biopharma spending patterns—where large pharmaceutical companies are redirecting dollars from commercialization (Definitive Healthcare's core focus) toward early-stage R&D and portfolio replenishment in response to patent expirations and funding constraints— a trend that management acknowledged as cyclical but potentially prolonged. The company's reliance on second-stage commercialization means it lacks direct exposure to the early-stage R&D green shoots noted by industry observers, creating a misalignment between where demand is emerging and where Definitive Healthcare Corp. plays, which could extend the segment's recovery beyond management's implied timeline and suppress overall growth even if provider and diversified markets improve.
The company's improving net dollar retention and win-back metrics, while positive, may be misleading indicators of sustainable recovery, as they are heavily influenced by cyclical renewal timing and the lapping of prior-year disruption rather than genuine organic demand expansion, and management's emphasis on these metrics risks obscuring the underlying weakness in new logo acquisition and long-term contract value. The decline in total remaining performance obligations (RPO) by 18% YoY and current RPO by 12% YoY—driven by a shift toward single-year deals over multiyear commitments—signals weakening customer confidence in the company's long-term value proposition, particularly in life sciences where multi-year contracts are critical for stabilizing revenue. This trend is exacerbated by the fact that professional services revenue growth, while strong (up 25% YoY in Q1 FY26), is inherently less predictable and lower-margin than subscription revenue, and its double-digit growth expectation does not offset the persistent drag from declining subscription bases. Furthermore, the benefit from the 2024 data partnership agreement, which provided ~2 points of revenue tailwind in Q1 FY26, will fully lap by Q2, meaning the year-over-year revenue decline is set to worsen to 8-9% in Q2 and remain at 6-9% for the full year, undermining narratives of imminent recovery.
Definitive Healthcare Corp.'s AI and digital activation initiatives, while promising in theory, face significant execution and monetization risks that could delay or diminish their financial impact, particularly given the lack of clarity on pricing strategy, customer adoption curves, and competitive differentiation in a crowded AI-enabled healthcare analytics market. Management's assertion that AI will serve primarily as a retention and value-enhancement tool—rather than an immediate pricing lever—suggests that near-term revenue uplift may be minimal, and the monetization path remains contingent on successful integration into customer workflows, user training, and demonstrable ROI, all of which are uncertain at this early stage. The company's digital activation business, though showing increased agency sign-ups (30+ with >50% active), remains nascent and unproven at scale, with revenue generation dependent on lengthy sales cycles and advertiser budgets that are sensitive to macroeconomic conditions. Moreover, the reliance on third-party benchmarks (e.g., 63% higher CTR) to validate audience performance does not guarantee translating engagement into sustained paid contracts, especially as competitors rapidly develop comparable AI-driven targeting capabilities. Without a clear, near-term monetization pathway for these innovations, the investments in AI and digital activation risk becoming prolonged overhead rather than catalysts for growth, especially if life sciences recovery fails to materialize as expected.

Definitive Healthcare Corp. continues to face persistent structural headwinds in its life sciences segment, which remains the primary driver of the company's overall revenue decline despite modest gains in diversified and provider markets, and management's optimism about a near-term turnaround may be overstated given the segment's delayed response to strategic initiatives and ongoing macroeconomic pressures. While the company highlights repaired claims data levels and early win-backs as signs of recovery, life sciences revenue remains depressed due to a fundamental shift in biopharma spending patterns—where large pharmaceutical companies are redirecting dollars from commercialization (Definitive Healthcare's core focus) toward early-stage R&D and portfolio replenishment in response to patent expirations and funding constraints— a trend that management acknowledged as cyclical but potentially prolonged. The company's reliance on second-stage commercialization means it lacks direct exposure to the early-stage R&D green shoots noted by industry observers, creating a misalignment between where demand is emerging and where Definitive Healthcare Corp. plays, which could extend the segment's recovery beyond management's implied timeline and suppress overall growth even if provider and diversified markets improve.
The company's improving net dollar retention and win-back metrics, while positive, may be misleading indicators of sustainable recovery, as they are heavily influenced by cyclical renewal timing and the lapping of prior-year disruption rather than genuine organic demand expansion, and management's emphasis on these metrics risks obscuring the underlying weakness in new logo acquisition and long-term contract value. The decline in total remaining performance obligations (RPO) by 18% YoY and current RPO by 12% YoY—driven by a shift toward single-year deals over multiyear commitments—signals weakening customer confidence in the company's long-term value proposition, particularly in life sciences where multi-year contracts are critical for stabilizing revenue. This trend is exacerbated by the fact that professional services revenue growth, while strong (up 25% YoY in Q1 FY26), is inherently less predictable and lower-margin than subscription revenue, and its double-digit growth expectation does not offset the persistent drag from declining subscription bases. Furthermore, the benefit from the 2024 data partnership agreement, which provided ~2 points of revenue tailwind in Q1 FY26, will fully lap by Q2, meaning the year-over-year revenue decline is set to worsen to 8-9% in Q2 and remain at 6-9% for the full year, undermining narratives of imminent recovery.
Definitive Healthcare Corp.'s AI and digital activation initiatives, while promising in theory, face significant execution and monetization risks that could delay or diminish their financial impact, particularly given the lack of clarity on pricing strategy, customer adoption curves, and competitive differentiation in a crowded AI-enabled healthcare analytics market. Management's assertion that AI will serve primarily as a retention and value-enhancement tool—rather than an immediate pricing lever—suggests that near-term revenue uplift may be minimal, and the monetization path remains contingent on successful integration into customer workflows, user training, and demonstrable ROI, all of which are uncertain at this early stage. The company's digital activation business, though showing increased agency sign-ups (30+ with >50% active), remains nascent and unproven at scale, with revenue generation dependent on lengthy sales cycles and advertiser budgets that are sensitive to macroeconomic conditions. Moreover, the reliance on third-party benchmarks (e.g., 63% higher CTR) to validate audience performance does not guarantee translating engagement into sustained paid contracts, especially as competitors rapidly develop comparable AI-driven targeting capabilities. Without a clear, near-term monetization pathway for these innovations, the investments in AI and digital activation risk becoming prolonged overhead rather than catalysts for growth, especially if life sciences recovery fails to materialize as expected.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password